nodes	percent_of_prediction	percent_of_DWPC	metapath
Loxapine—SLC6A3—malignant glioma	0.58	1	CbGaD
Loxapine—HTR1D—meninx—malignant glioma	0.0154	0.0711	CbGeAlD
Loxapine—HTR3A—fourth ventricle—malignant glioma	0.015	0.0692	CbGeAlD
Loxapine—HTR1B—dura mater—malignant glioma	0.0146	0.0675	CbGeAlD
Loxapine—HTR1D—dura mater—malignant glioma	0.0142	0.0654	CbGeAlD
Loxapine—HTR2C—choroid plexus—malignant glioma	0.0119	0.0551	CbGeAlD
Loxapine—DRD3—telencephalic ventricle—malignant glioma	0.00628	0.029	CbGeAlD
Loxapine—HTR2A—choroid plexus—malignant glioma	0.00598	0.0276	CbGeAlD
Loxapine—DRD1—telencephalic ventricle—malignant glioma	0.0045	0.0208	CbGeAlD
Loxapine—HTR1B—telencephalic ventricle—malignant glioma	0.00364	0.0168	CbGeAlD
Loxapine—SLC6A3—telencephalic ventricle—malignant glioma	0.00361	0.0167	CbGeAlD
Loxapine—HTR1D—telencephalic ventricle—malignant glioma	0.00353	0.0163	CbGeAlD
Loxapine—HTR2C—telencephalic ventricle—malignant glioma	0.00349	0.0161	CbGeAlD
Loxapine—HTR7—pons—malignant glioma	0.00341	0.0158	CbGeAlD
Loxapine—HTR2A—cerebellar cortex—malignant glioma	0.00301	0.0139	CbGeAlD
Loxapine—HTR1A—telencephalic ventricle—malignant glioma	0.00294	0.0136	CbGeAlD
Loxapine—HTR7—telencephalic ventricle—malignant glioma	0.00281	0.013	CbGeAlD
Loxapine—DRD2—telencephalic ventricle—malignant glioma	0.00266	0.0123	CbGeAlD
Loxapine—HTR5A—central nervous system—malignant glioma	0.00246	0.0114	CbGeAlD
Loxapine—HTR2A—pons—malignant glioma	0.00213	0.00983	CbGeAlD
Loxapine—Trifluoperazine—CALY—malignant glioma	0.00212	0.281	CrCbGaD
Loxapine—HTR2A—vertebral column—malignant glioma	0.00211	0.00976	CbGeAlD
Loxapine—HTR1E—brainstem—malignant glioma	0.00208	0.00962	CbGeAlD
Loxapine—HTR5A—brain—malignant glioma	0.00196	0.00903	CbGeAlD
Loxapine—HTR1E—telencephalon—malignant glioma	0.00185	0.00854	CbGeAlD
Loxapine—HTR1B—blood vessel—malignant glioma	0.0018	0.00833	CbGeAlD
Loxapine—Clozapine—CALY—malignant glioma	0.00177	0.234	CrCbGaD
Loxapine—HTR2A—telencephalic ventricle—malignant glioma	0.00175	0.00809	CbGeAlD
Loxapine—HTR1D—blood vessel—malignant glioma	0.00175	0.00806	CbGeAlD
Loxapine—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00162	0.0394	CcSEcCtD
Loxapine—HTR2A—pineal body—malignant glioma	0.00152	0.00702	CbGeAlD
Loxapine—HTR7—endothelium—malignant glioma	0.00151	0.00696	CbGeAlD
Loxapine—Liver injury—Temozolomide—malignant glioma	0.00145	0.0353	CcSEcCtD
Loxapine—HTR6—telencephalon—malignant glioma	0.00145	0.0067	CbGeAlD
Loxapine—DRD5—telencephalon—malignant glioma	0.00141	0.00653	CbGeAlD
Loxapine—Amenorrhoea—Temozolomide—malignant glioma	0.00139	0.0338	CcSEcCtD
Loxapine—HTR7—blood vessel—malignant glioma	0.00139	0.00642	CbGeAlD
Loxapine—Gait disturbance—Carmustine—malignant glioma	0.0013	0.0315	CcSEcCtD
Loxapine—Gait disturbance—Temozolomide—malignant glioma	0.00125	0.0304	CcSEcCtD
Loxapine—DRD1—brainstem—malignant glioma	0.00122	0.00562	CbGeAlD
Loxapine—HTR3A—brainstem—malignant glioma	0.00117	0.00543	CbGeAlD
Loxapine—Gynaecomastia—Carmustine—malignant glioma	0.00113	0.0275	CcSEcCtD
Loxapine—Dry eye—Temozolomide—malignant glioma	0.00113	0.0274	CcSEcCtD
Loxapine—DRD1—telencephalon—malignant glioma	0.00108	0.00499	CbGeAlD
Loxapine—HTR1E—central nervous system—malignant glioma	0.00105	0.00486	CbGeAlD
Loxapine—HTR3A—telencephalon—malignant glioma	0.00104	0.00482	CbGeAlD
Loxapine—HTR1B—brainstem—malignant glioma	0.000986	0.00455	CbGeAlD
Loxapine—SLC6A3—brainstem—malignant glioma	0.000978	0.00452	CbGeAlD
Loxapine—Nasal congestion—Temozolomide—malignant glioma	0.000974	0.0237	CcSEcCtD
Loxapine—DRD4—brain—malignant glioma	0.000968	0.00447	CbGeAlD
Loxapine—HTR1D—brainstem—malignant glioma	0.000954	0.00441	CbGeAlD
Loxapine—HTR2C—brainstem—malignant glioma	0.000945	0.00436	CbGeAlD
Loxapine—HTR2A—endothelium—malignant glioma	0.00094	0.00434	CbGeAlD
Loxapine—CHRM4—central nervous system—malignant glioma	0.000922	0.00426	CbGeAlD
Loxapine—SLC6A4—brainstem—malignant glioma	0.000896	0.00414	CbGeAlD
Loxapine—HTR1B—telencephalon—malignant glioma	0.000875	0.00404	CbGeAlD
Loxapine—CHRM2—telencephalon—malignant glioma	0.00087	0.00402	CbGeAlD
Loxapine—SLC6A3—telencephalon—malignant glioma	0.000868	0.00401	CbGeAlD
Loxapine—HTR2A—blood vessel—malignant glioma	0.000867	0.00401	CbGeAlD
Loxapine—DRD3—central nervous system—malignant glioma	0.000857	0.00396	CbGeAlD
Loxapine—HTR1D—telencephalon—malignant glioma	0.000847	0.00391	CbGeAlD
Loxapine—HTR2C—telencephalon—malignant glioma	0.000839	0.00387	CbGeAlD
Loxapine—HTR1E—brain—malignant glioma	0.000835	0.00385	CbGeAlD
Loxapine—HTR6—central nervous system—malignant glioma	0.000825	0.00381	CbGeAlD
Loxapine—ADRB1—telencephalon—malignant glioma	0.000823	0.0038	CbGeAlD
Loxapine—DRD5—central nervous system—malignant glioma	0.000803	0.00371	CbGeAlD
Loxapine—HTR1A—brainstem—malignant glioma	0.000795	0.00367	CbGeAlD
Loxapine—SLC6A4—telencephalon—malignant glioma	0.000795	0.00367	CbGeAlD
Loxapine—Dysphagia—Carmustine—malignant glioma	0.000794	0.0193	CcSEcCtD
Loxapine—CHRM1—telencephalon—malignant glioma	0.000792	0.00366	CbGeAlD
Loxapine—SLC6A2—brainstem—malignant glioma	0.000789	0.00364	CbGeAlD
Loxapine—DRD1—midbrain—malignant glioma	0.000775	0.00358	CbGeAlD
Loxapine—Dysphagia—Temozolomide—malignant glioma	0.000767	0.0186	CcSEcCtD
Loxapine—HTR7—brainstem—malignant glioma	0.00076	0.00351	CbGeAlD
Loxapine—HRH2—central nervous system—malignant glioma	0.000754	0.00348	CbGeAlD
Loxapine—ADRA1A—brainstem—malignant glioma	0.000733	0.00339	CbGeAlD
Loxapine—CHRM4—brain—malignant glioma	0.000732	0.00338	CbGeAlD
Loxapine—Clobazam—CYP2C18—malignant glioma	0.000722	0.0955	CrCbGaD
Loxapine—CHRM5—central nervous system—malignant glioma	0.00072	0.00333	CbGeAlD
Loxapine—DRD2—brainstem—malignant glioma	0.000719	0.00332	CbGeAlD
Loxapine—CHRM3—telencephalon—malignant glioma	0.000709	0.00327	CbGeAlD
Loxapine—HTR1A—telencephalon—malignant glioma	0.000706	0.00326	CbGeAlD
Loxapine—Photosensitivity reaction—Temozolomide—malignant glioma	0.0007	0.017	CcSEcCtD
Loxapine—SLC6A2—telencephalon—malignant glioma	0.0007	0.00323	CbGeAlD
Loxapine—Weight increased—Temozolomide—malignant glioma	0.000698	0.017	CcSEcCtD
Loxapine—Renal failure—Carmustine—malignant glioma	0.000696	0.0169	CcSEcCtD
Loxapine—Weight decreased—Temozolomide—malignant glioma	0.000694	0.0169	CcSEcCtD
Loxapine—DRD2—retina—malignant glioma	0.000693	0.0032	CbGeAlD
Loxapine—Azelastine—CYP2B6—malignant glioma	0.000689	0.0912	CrCbGaD
Loxapine—DRD3—brain—malignant glioma	0.00068	0.00314	CbGeAlD
Loxapine—HTR7—telencephalon—malignant glioma	0.000675	0.00312	CbGeAlD
Loxapine—HTR2C—medulla oblongata—malignant glioma	0.000659	0.00304	CbGeAlD
Loxapine—ADRA1B—central nervous system—malignant glioma	0.000658	0.00304	CbGeAlD
Loxapine—HTR6—brain—malignant glioma	0.000655	0.00302	CbGeAlD
Loxapine—ADRA1A—telencephalon—malignant glioma	0.000651	0.00301	CbGeAlD
Loxapine—DRD2—telencephalon—malignant glioma	0.000638	0.00295	CbGeAlD
Loxapine—DRD5—brain—malignant glioma	0.000638	0.00294	CbGeAlD
Loxapine—Hypoaesthesia—Carmustine—malignant glioma	0.000632	0.0153	CcSEcCtD
Loxapine—HTR1B—midbrain—malignant glioma	0.000628	0.0029	CbGeAlD
Loxapine—SLC6A3—midbrain—malignant glioma	0.000623	0.00288	CbGeAlD
Loxapine—ADRA2C—telencephalon—malignant glioma	0.00062	0.00286	CbGeAlD
Loxapine—Hepatitis—Temozolomide—malignant glioma	0.000614	0.0149	CcSEcCtD
Loxapine—DRD1—central nervous system—malignant glioma	0.000614	0.00283	CbGeAlD
Loxapine—HTR1B—spinal cord—malignant glioma	0.000613	0.00283	CbGeAlD
Loxapine—Hypoaesthesia—Temozolomide—malignant glioma	0.000611	0.0148	CcSEcCtD
Loxapine—HTR1D—midbrain—malignant glioma	0.000608	0.00281	CbGeAlD
Loxapine—SLC6A3—spinal cord—malignant glioma	0.000608	0.00281	CbGeAlD
Loxapine—HTR2C—midbrain—malignant glioma	0.000602	0.00278	CbGeAlD
Loxapine—HRH2—brain—malignant glioma	0.000599	0.00277	CbGeAlD
Loxapine—HTR3A—central nervous system—malignant glioma	0.000593	0.00274	CbGeAlD
Loxapine—HTR2C—spinal cord—malignant glioma	0.000588	0.00271	CbGeAlD
Loxapine—CHRM5—brain—malignant glioma	0.000572	0.00264	CbGeAlD
Loxapine—SLC6A4—midbrain—malignant glioma	0.000571	0.00264	CbGeAlD
Loxapine—Alopecia—Carmustine—malignant glioma	0.000562	0.0136	CcSEcCtD
Loxapine—Angiopathy—Temozolomide—malignant glioma	0.000557	0.0135	CcSEcCtD
Loxapine—SLC6A4—spinal cord—malignant glioma	0.000557	0.00257	CbGeAlD
Loxapine—Mediastinal disorder—Temozolomide—malignant glioma	0.000553	0.0134	CcSEcCtD
Loxapine—SLC6A2—medulla oblongata—malignant glioma	0.00055	0.00254	CbGeAlD
Loxapine—Alopecia—Temozolomide—malignant glioma	0.000543	0.0132	CcSEcCtD
Loxapine—Clobazam—CYP2B6—malignant glioma	0.000536	0.0709	CrCbGaD
Loxapine—HTR7—medulla oblongata—malignant glioma	0.00053	0.00245	CbGeAlD
Loxapine—Dysgeusia—Temozolomide—malignant glioma	0.000524	0.0127	CcSEcCtD
Loxapine—ADRA1B—brain—malignant glioma	0.000523	0.00241	CbGeAlD
Loxapine—Vision blurred—Carmustine—malignant glioma	0.000521	0.0127	CcSEcCtD
Loxapine—Tremor—Carmustine—malignant glioma	0.000518	0.0126	CcSEcCtD
Loxapine—HTR2A—embryo—malignant glioma	0.000517	0.00239	CbGeAlD
Loxapine—Agitation—Carmustine—malignant glioma	0.000508	0.0123	CcSEcCtD
Loxapine—HTR1A—midbrain—malignant glioma	0.000507	0.00234	CbGeAlD
Loxapine—Vision blurred—Temozolomide—malignant glioma	0.000504	0.0122	CcSEcCtD
Loxapine—HRH1—telencephalon—malignant glioma	0.000504	0.00233	CbGeAlD
Loxapine—Tremor—Temozolomide—malignant glioma	0.000501	0.0122	CcSEcCtD
Loxapine—HTR1B—central nervous system—malignant glioma	0.000497	0.0023	CbGeAlD
Loxapine—Leukopenia—Carmustine—malignant glioma	0.000495	0.012	CcSEcCtD
Loxapine—ADRA2A—telencephalon—malignant glioma	0.000495	0.00229	CbGeAlD
Loxapine—HTR1A—spinal cord—malignant glioma	0.000495	0.00228	CbGeAlD
Loxapine—CHRM2—central nervous system—malignant glioma	0.000495	0.00228	CbGeAlD
Loxapine—SLC6A3—central nervous system—malignant glioma	0.000493	0.00228	CbGeAlD
Loxapine—Agitation—Temozolomide—malignant glioma	0.000491	0.0119	CcSEcCtD
Loxapine—ADRA2C—medulla oblongata—malignant glioma	0.000487	0.00225	CbGeAlD
Loxapine—DRD1—brain—malignant glioma	0.000487	0.00225	CbGeAlD
Loxapine—HTR7—midbrain—malignant glioma	0.000484	0.00224	CbGeAlD
Loxapine—SLC6A3—cerebellum—malignant glioma	0.000482	0.00223	CbGeAlD
Loxapine—HTR1D—central nervous system—malignant glioma	0.000481	0.00222	CbGeAlD
Loxapine—Convulsion—Carmustine—malignant glioma	0.000479	0.0116	CcSEcCtD
Loxapine—Leukopenia—Temozolomide—malignant glioma	0.000479	0.0116	CcSEcCtD
Loxapine—Hypertension—Carmustine—malignant glioma	0.000478	0.0116	CcSEcCtD
Loxapine—HTR2C—central nervous system—malignant glioma	0.000477	0.0022	CbGeAlD
Loxapine—HTR2A—brainstem—malignant glioma	0.000474	0.00219	CbGeAlD
Loxapine—HTR7—spinal cord—malignant glioma	0.000473	0.00218	CbGeAlD
Loxapine—Chest pain—Carmustine—malignant glioma	0.000471	0.0114	CcSEcCtD
Loxapine—HTR3A—brain—malignant glioma	0.00047	0.00217	CbGeAlD
Loxapine—ADRB1—central nervous system—malignant glioma	0.000468	0.00216	CbGeAlD
Loxapine—Cough—Temozolomide—malignant glioma	0.000467	0.0113	CcSEcCtD
Loxapine—Convulsion—Temozolomide—malignant glioma	0.000463	0.0112	CcSEcCtD
Loxapine—Hypertension—Temozolomide—malignant glioma	0.000462	0.0112	CcSEcCtD
Loxapine—DRD2—midbrain—malignant glioma	0.000458	0.00212	CbGeAlD
Loxapine—HTR2A—retina—malignant glioma	0.000457	0.00211	CbGeAlD
Loxapine—Confusional state—Carmustine—malignant glioma	0.000455	0.0111	CcSEcCtD
Loxapine—SLC6A4—central nervous system—malignant glioma	0.000452	0.00209	CbGeAlD
Loxapine—Oedema—Carmustine—malignant glioma	0.000451	0.011	CcSEcCtD
Loxapine—CHRM1—central nervous system—malignant glioma	0.00045	0.00208	CbGeAlD
Loxapine—ADRA2C—midbrain—malignant glioma	0.000445	0.00206	CbGeAlD
Loxapine—Dry mouth—Temozolomide—malignant glioma	0.000445	0.0108	CcSEcCtD
Loxapine—Thrombocytopenia—Carmustine—malignant glioma	0.000442	0.0107	CcSEcCtD
Loxapine—Tachycardia—Carmustine—malignant glioma	0.000441	0.0107	CcSEcCtD
Loxapine—Confusional state—Temozolomide—malignant glioma	0.00044	0.0107	CcSEcCtD
Loxapine—Oedema—Temozolomide—malignant glioma	0.000436	0.0106	CcSEcCtD
Loxapine—ADRA2C—spinal cord—malignant glioma	0.000434	0.00201	CbGeAlD
Loxapine—Nervous system disorder—Temozolomide—malignant glioma	0.000428	0.0104	CcSEcCtD
Loxapine—Thrombocytopenia—Temozolomide—malignant glioma	0.000427	0.0104	CcSEcCtD
Loxapine—Hypotension—Carmustine—malignant glioma	0.000422	0.0102	CcSEcCtD
Loxapine—Diazepam—CYP2C18—malignant glioma	0.000422	0.0558	CrCbGaD
Loxapine—HTR2A—telencephalon—malignant glioma	0.000421	0.00194	CbGeAlD
Loxapine—Insomnia—Carmustine—malignant glioma	0.000408	0.00991	CcSEcCtD
Loxapine—Paraesthesia—Carmustine—malignant glioma	0.000405	0.00984	CcSEcCtD
Loxapine—CHRM3—central nervous system—malignant glioma	0.000403	0.00186	CbGeAlD
Loxapine—Dyspnoea—Carmustine—malignant glioma	0.000403	0.00977	CcSEcCtD
Loxapine—Amoxapine—SLC6A3—malignant glioma	0.000402	0.0531	CrCbGaD
Loxapine—Somnolence—Carmustine—malignant glioma	0.000401	0.00974	CcSEcCtD
Loxapine—HTR1A—central nervous system—malignant glioma	0.000401	0.00185	CbGeAlD
Loxapine—SLC6A2—central nervous system—malignant glioma	0.000398	0.00184	CbGeAlD
Loxapine—HTR1B—brain—malignant glioma	0.000395	0.00182	CbGeAlD
Loxapine—Insomnia—Temozolomide—malignant glioma	0.000395	0.00958	CcSEcCtD
Loxapine—CHRM2—brain—malignant glioma	0.000393	0.00181	CbGeAlD
Loxapine—HTR1A—cerebellum—malignant glioma	0.000392	0.00181	CbGeAlD
Loxapine—Paraesthesia—Temozolomide—malignant glioma	0.000392	0.00951	CcSEcCtD
Loxapine—SLC6A3—brain—malignant glioma	0.000391	0.00181	CbGeAlD
Loxapine—Gastrointestinal disorder—Carmustine—malignant glioma	0.00039	0.00946	CcSEcCtD
Loxapine—Dyspnoea—Temozolomide—malignant glioma	0.000389	0.00944	CcSEcCtD
Loxapine—ADRA2A—medulla oblongata—malignant glioma	0.000389	0.0018	CbGeAlD
Loxapine—Somnolence—Temozolomide—malignant glioma	0.000388	0.00942	CcSEcCtD
Loxapine—Constipation—Carmustine—malignant glioma	0.000386	0.00937	CcSEcCtD
Loxapine—HTR7—central nervous system—malignant glioma	0.000383	0.00177	CbGeAlD
Loxapine—HTR1D—brain—malignant glioma	0.000382	0.00177	CbGeAlD
Loxapine—HTR2C—brain—malignant glioma	0.000378	0.00175	CbGeAlD
Loxapine—Temazepam—CYP2B6—malignant glioma	0.000377	0.0498	CrCbGaD
Loxapine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000377	0.00914	CcSEcCtD
Loxapine—Fatigue—Temozolomide—malignant glioma	0.000376	0.00913	CcSEcCtD
Loxapine—HTR7—cerebellum—malignant glioma	0.000375	0.00173	CbGeAlD
Loxapine—Constipation—Temozolomide—malignant glioma	0.000373	0.00906	CcSEcCtD
Loxapine—Feeling abnormal—Carmustine—malignant glioma	0.000372	0.00903	CcSEcCtD
Loxapine—ADRB1—brain—malignant glioma	0.000371	0.00172	CbGeAlD
Loxapine—ADRA1A—central nervous system—malignant glioma	0.00037	0.00171	CbGeAlD
Loxapine—DRD2—central nervous system—malignant glioma	0.000363	0.00167	CbGeAlD
Loxapine—ADRA1A—cerebellum—malignant glioma	0.000361	0.00167	CbGeAlD
Loxapine—Feeling abnormal—Temozolomide—malignant glioma	0.00036	0.00873	CcSEcCtD
Loxapine—SLC6A4—brain—malignant glioma	0.000359	0.00166	CbGeAlD
Loxapine—CHRM1—brain—malignant glioma	0.000357	0.00165	CbGeAlD
Loxapine—ADRA2A—midbrain—malignant glioma	0.000355	0.00164	CbGeAlD
Loxapine—DRD2—cerebellum—malignant glioma	0.000354	0.00164	CbGeAlD
Loxapine—ADRA2C—central nervous system—malignant glioma	0.000352	0.00163	CbGeAlD
Loxapine—ADRA2A—spinal cord—malignant glioma	0.000347	0.0016	CbGeAlD
Loxapine—ADRA2C—cerebellum—malignant glioma	0.000344	0.00159	CbGeAlD
Loxapine—Hypersensitivity—Carmustine—malignant glioma	0.000333	0.00808	CcSEcCtD
Loxapine—HTR2A—medulla oblongata—malignant glioma	0.000331	0.00153	CbGeAlD
Loxapine—Asthenia—Carmustine—malignant glioma	0.000324	0.00786	CcSEcCtD
Loxapine—Hypersensitivity—Temozolomide—malignant glioma	0.000321	0.0078	CcSEcCtD
Loxapine—CHRM3—brain—malignant glioma	0.00032	0.00148	CbGeAlD
Loxapine—HTR1A—brain—malignant glioma	0.000319	0.00147	CbGeAlD
Loxapine—SLC6A2—brain—malignant glioma	0.000316	0.00146	CbGeAlD
Loxapine—Asthenia—Temozolomide—malignant glioma	0.000313	0.0076	CcSEcCtD
Loxapine—Diazepam—CYP2B6—malignant glioma	0.000313	0.0414	CrCbGaD
Loxapine—Pruritus—Temozolomide—malignant glioma	0.000309	0.00749	CcSEcCtD
Loxapine—HTR7—brain—malignant glioma	0.000304	0.00141	CbGeAlD
Loxapine—HTR2A—midbrain—malignant glioma	0.000302	0.0014	CbGeAlD
Loxapine—Dizziness—Carmustine—malignant glioma	0.000299	0.00725	CcSEcCtD
Loxapine—HTR2A—spinal cord—malignant glioma	0.000295	0.00136	CbGeAlD
Loxapine—ADRA1A—brain—malignant glioma	0.000294	0.00136	CbGeAlD
Loxapine—Dizziness—Temozolomide—malignant glioma	0.000289	0.007	CcSEcCtD
Loxapine—DRD2—brain—malignant glioma	0.000288	0.00133	CbGeAlD
Loxapine—Vomiting—Carmustine—malignant glioma	0.000287	0.00697	CcSEcCtD
Loxapine—HRH1—central nervous system—malignant glioma	0.000286	0.00132	CbGeAlD
Loxapine—Rash—Carmustine—malignant glioma	0.000285	0.00691	CcSEcCtD
Loxapine—Dermatitis—Carmustine—malignant glioma	0.000284	0.0069	CcSEcCtD
Loxapine—Headache—Carmustine—malignant glioma	0.000283	0.00687	CcSEcCtD
Loxapine—ADRA2A—central nervous system—malignant glioma	0.000281	0.0013	CbGeAlD
Loxapine—ADRA2C—brain—malignant glioma	0.00028	0.00129	CbGeAlD
Loxapine—Vomiting—Temozolomide—malignant glioma	0.000277	0.00673	CcSEcCtD
Loxapine—Rash—Temozolomide—malignant glioma	0.000275	0.00668	CcSEcCtD
Loxapine—ADRA2A—cerebellum—malignant glioma	0.000275	0.00127	CbGeAlD
Loxapine—Dermatitis—Temozolomide—malignant glioma	0.000275	0.00667	CcSEcCtD
Loxapine—Headache—Temozolomide—malignant glioma	0.000273	0.00664	CcSEcCtD
Loxapine—Nausea—Carmustine—malignant glioma	0.000268	0.00651	CcSEcCtD
Loxapine—Nausea—Temozolomide—malignant glioma	0.000259	0.00629	CcSEcCtD
Loxapine—HTR2A—central nervous system—malignant glioma	0.000239	0.0011	CbGeAlD
Loxapine—HTR2A—cerebellum—malignant glioma	0.000234	0.00108	CbGeAlD
Loxapine—HRH1—brain—malignant glioma	0.000227	0.00105	CbGeAlD
Loxapine—ADRA2A—brain—malignant glioma	0.000223	0.00103	CbGeAlD
Loxapine—Diazepam—PTGS1—malignant glioma	0.000206	0.0272	CrCbGaD
Loxapine—HTR2A—brain—malignant glioma	0.00019	0.000877	CbGeAlD
Loxapine—ADRA1B—Signaling Pathways—IL2—malignant glioma	5.78e-06	3.75e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—ERBB2—malignant glioma	5.77e-06	3.74e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling by GPCR—AKT1—malignant glioma	5.77e-06	3.74e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—PIK3CA—malignant glioma	5.77e-06	3.74e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MDM2—malignant glioma	5.76e-06	3.73e-05	CbGpPWpGaD
Loxapine—DRD5—Signaling Pathways—AKT1—malignant glioma	5.76e-06	3.73e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—KRAS—malignant glioma	5.76e-06	3.73e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—ERBB2—malignant glioma	5.75e-06	3.73e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MDM2—malignant glioma	5.75e-06	3.72e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MMP9—malignant glioma	5.74e-06	3.72e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—RAF1—malignant glioma	5.74e-06	3.72e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—ERBB2—malignant glioma	5.74e-06	3.72e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—RAF1—malignant glioma	5.73e-06	3.71e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MMP9—malignant glioma	5.71e-06	3.7e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PTEN—malignant glioma	5.71e-06	3.7e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	5.71e-06	3.7e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—FGF2—malignant glioma	5.71e-06	3.7e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CB—malignant glioma	5.7e-06	3.69e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PTEN—malignant glioma	5.68e-06	3.68e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—ERBB2—malignant glioma	5.68e-06	3.68e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CB—malignant glioma	5.68e-06	3.68e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—EGFR—malignant glioma	5.66e-06	3.67e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—ERBB2—malignant glioma	5.66e-06	3.67e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—KRAS—malignant glioma	5.66e-06	3.67e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CB—malignant glioma	5.66e-06	3.67e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CB—malignant glioma	5.61e-06	3.63e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CB—malignant glioma	5.59e-06	3.62e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—KRAS—malignant glioma	5.59e-06	3.62e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CXCL8—malignant glioma	5.58e-06	3.61e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling by GPCR—AKT1—malignant glioma	5.57e-06	3.61e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MMP9—malignant glioma	5.56e-06	3.6e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling by GPCR—AKT1—malignant glioma	5.54e-06	3.59e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PTEN—malignant glioma	5.53e-06	3.58e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—MYC—malignant glioma	5.52e-06	3.58e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CXCL8—malignant glioma	5.49e-06	3.56e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CXCL8—malignant glioma	5.47e-06	3.55e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MMP9—malignant glioma	5.47e-06	3.54e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CXCL8—malignant glioma	5.46e-06	3.54e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—MYC—malignant glioma	5.44e-06	3.53e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—PIK3CA—malignant glioma	5.44e-06	3.53e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CXCL8—malignant glioma	5.44e-06	3.53e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PTEN—malignant glioma	5.44e-06	3.52e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—PIK3CA—malignant glioma	5.44e-06	3.52e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—PIK3CA—malignant glioma	5.4e-06	3.5e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—EGFR—malignant glioma	5.4e-06	3.5e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—VEGFA—malignant glioma	5.39e-06	3.49e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling by GPCR—AKT1—malignant glioma	5.39e-06	3.49e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CXCL8—malignant glioma	5.39e-06	3.49e-05	CbGpPWpGaD
Loxapine—DRD2—GPCR downstream signaling—AKT1—malignant glioma	5.39e-06	3.49e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CXCL8—malignant glioma	5.37e-06	3.48e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PTEN—malignant glioma	5.37e-06	3.48e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	5.36e-06	3.47e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—KRAS—malignant glioma	5.35e-06	3.47e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—VEGFA—malignant glioma	5.34e-06	3.46e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—STAT3—malignant glioma	5.34e-06	3.46e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MDM2—malignant glioma	5.34e-06	3.46e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—CASP3—malignant glioma	5.34e-06	3.46e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—IL2—malignant glioma	5.33e-06	3.45e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—EGFR—malignant glioma	5.33e-06	3.45e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—RAF1—malignant glioma	5.32e-06	3.45e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling by GPCR—AKT1—malignant glioma	5.31e-06	3.44e-05	CbGpPWpGaD
Loxapine—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	5.3e-06	3.43e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—STAT3—malignant glioma	5.29e-06	3.43e-05	CbGpPWpGaD
Loxapine—HRH1—GPCR downstream signaling—AKT1—malignant glioma	5.29e-06	3.43e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—PIK3CA—malignant glioma	5.29e-06	3.43e-05	CbGpPWpGaD
Loxapine—CHRM1—GPCR downstream signaling—AKT1—malignant glioma	5.27e-06	3.42e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—TP53—malignant glioma	5.26e-06	3.41e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	5.26e-06	3.41e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—TP53—malignant glioma	5.26e-06	3.41e-05	CbGpPWpGaD
Loxapine—CHRM3—GPCR downstream signaling—AKT1—malignant glioma	5.25e-06	3.41e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—CASP3—malignant glioma	5.25e-06	3.4e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—IL2—malignant glioma	5.24e-06	3.4e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—CASP3—malignant glioma	5.24e-06	3.4e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—IL2—malignant glioma	5.23e-06	3.39e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—TP53—malignant glioma	5.22e-06	3.39e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—CASP3—malignant glioma	5.22e-06	3.38e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—IL2—malignant glioma	5.21e-06	3.38e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—CASP3—malignant glioma	5.21e-06	3.37e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—PIK3CA—malignant glioma	5.2e-06	3.37e-05	CbGpPWpGaD
Loxapine—CHRM2—GPCR downstream signaling—AKT1—malignant glioma	5.2e-06	3.37e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—IL2—malignant glioma	5.2e-06	3.37e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	5.19e-06	3.37e-05	CbGpPWpGaD
Loxapine—ADRA1A—GPCR downstream signaling—AKT1—malignant glioma	5.19e-06	3.36e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—VEGFA—malignant glioma	5.16e-06	3.34e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—CASP3—malignant glioma	5.16e-06	3.34e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—IL2—malignant glioma	5.15e-06	3.34e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—CASP3—malignant glioma	5.14e-06	3.33e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—IL2—malignant glioma	5.13e-06	3.33e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—PIK3CA—malignant glioma	5.13e-06	3.33e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—VEGFA—malignant glioma	5.13e-06	3.33e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—TP53—malignant glioma	5.12e-06	3.32e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—STAT3—malignant glioma	5.11e-06	3.31e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—KRAS—malignant glioma	5.1e-06	3.3e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—STAT3—malignant glioma	5.08e-06	3.29e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MMP9—malignant glioma	5.04e-06	3.27e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—TP53—malignant glioma	5.03e-06	3.26e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—KRAS—malignant glioma	5.03e-06	3.26e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PTEN—malignant glioma	5.01e-06	3.25e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	4.99e-06	3.23e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—VEGFA—malignant glioma	4.99e-06	3.23e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—TP53—malignant glioma	4.97e-06	3.22e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MMP9—malignant glioma	4.96e-06	3.22e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—MYC—malignant glioma	4.96e-06	3.22e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MMP9—malignant glioma	4.95e-06	3.21e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—STAT3—malignant glioma	4.94e-06	3.2e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MMP9—malignant glioma	4.94e-06	3.2e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PTEN—malignant glioma	4.93e-06	3.2e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PTEN—malignant glioma	4.92e-06	3.19e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MMP9—malignant glioma	4.92e-06	3.19e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—PIK3CA—malignant glioma	4.92e-06	3.19e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—MYC—malignant glioma	4.92e-06	3.19e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—VEGFA—malignant glioma	4.91e-06	3.18e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PTEN—malignant glioma	4.91e-06	3.18e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling by GPCR—AKT1—malignant glioma	4.89e-06	3.17e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PTEN—malignant glioma	4.89e-06	3.17e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MMP9—malignant glioma	4.87e-06	3.16e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—STAT3—malignant glioma	4.86e-06	3.15e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MMP9—malignant glioma	4.86e-06	3.15e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—EGFR—malignant glioma	4.85e-06	3.14e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PTEN—malignant glioma	4.84e-06	3.14e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PTEN—malignant glioma	4.83e-06	3.13e-05	CbGpPWpGaD
Loxapine—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	4.82e-06	3.12e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling by GPCR—AKT1—malignant glioma	4.81e-06	3.12e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—EGFR—malignant glioma	4.81e-06	3.12e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling by GPCR—AKT1—malignant glioma	4.8e-06	3.11e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling by GPCR—AKT1—malignant glioma	4.79e-06	3.1e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—CASP3—malignant glioma	4.78e-06	3.1e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling by GPCR—AKT1—malignant glioma	4.77e-06	3.09e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—IL2—malignant glioma	4.77e-06	3.09e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—TP53—malignant glioma	4.76e-06	3.08e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—MYC—malignant glioma	4.75e-06	3.08e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling by GPCR—AKT1—malignant glioma	4.73e-06	3.06e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—MYC—malignant glioma	4.72e-06	3.06e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling by GPCR—AKT1—malignant glioma	4.71e-06	3.05e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—PIK3CA—malignant glioma	4.68e-06	3.04e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—PIK3CA—malignant glioma	4.66e-06	3.02e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—EGFR—malignant glioma	4.64e-06	3.01e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—PIK3CA—malignant glioma	4.62e-06	3e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—EGFR—malignant glioma	4.62e-06	2.99e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—MYC—malignant glioma	4.59e-06	2.98e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—KRAS—malignant glioma	4.58e-06	2.97e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—KRAS—malignant glioma	4.54e-06	2.94e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—TP53—malignant glioma	4.53e-06	2.94e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—VEGFA—malignant glioma	4.53e-06	2.93e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—MYC—malignant glioma	4.52e-06	2.93e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MMP9—malignant glioma	4.51e-06	2.93e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—EGFR—malignant glioma	4.49e-06	2.91e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PTEN—malignant glioma	4.49e-06	2.91e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—STAT3—malignant glioma	4.48e-06	2.91e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—TP53—malignant glioma	4.47e-06	2.9e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—VEGFA—malignant glioma	4.46e-06	2.89e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—VEGFA—malignant glioma	4.45e-06	2.88e-05	CbGpPWpGaD
Loxapine—HTR6—Signaling Pathways—AKT1—malignant glioma	4.45e-06	2.88e-05	CbGpPWpGaD
Loxapine—HTR7—Signaling Pathways—AKT1—malignant glioma	4.44e-06	2.88e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—VEGFA—malignant glioma	4.43e-06	2.87e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—EGFR—malignant glioma	4.42e-06	2.86e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—VEGFA—malignant glioma	4.42e-06	2.86e-05	CbGpPWpGaD
Loxapine—HTR1D—Signaling Pathways—AKT1—malignant glioma	4.41e-06	2.86e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—STAT3—malignant glioma	4.41e-06	2.86e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—STAT3—malignant glioma	4.4e-06	2.85e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—STAT3—malignant glioma	4.39e-06	2.84e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—KRAS—malignant glioma	4.38e-06	2.84e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	4.38e-06	2.84e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—VEGFA—malignant glioma	4.37e-06	2.84e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—STAT3—malignant glioma	4.37e-06	2.83e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—VEGFA—malignant glioma	4.36e-06	2.83e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—KRAS—malignant glioma	4.36e-06	2.83e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—STAT3—malignant glioma	4.33e-06	2.81e-05	CbGpPWpGaD
Loxapine—HTR1B—Signaling Pathways—AKT1—malignant glioma	4.32e-06	2.8e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—STAT3—malignant glioma	4.32e-06	2.8e-05	CbGpPWpGaD
Loxapine—DRD4—Signaling Pathways—AKT1—malignant glioma	4.25e-06	2.75e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—KRAS—malignant glioma	4.24e-06	2.75e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—PIK3CA—malignant glioma	4.21e-06	2.73e-05	CbGpPWpGaD
Loxapine—CHRM4—Signaling Pathways—AKT1—malignant glioma	4.19e-06	2.72e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—KRAS—malignant glioma	4.18e-06	2.71e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—PIK3CA—malignant glioma	4.17e-06	2.7e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—MYC—malignant glioma	4.17e-06	2.7e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—PIK3CA—malignant glioma	4.13e-06	2.67e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—MYC—malignant glioma	4.1e-06	2.66e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—MYC—malignant glioma	4.09e-06	2.65e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—MYC—malignant glioma	4.08e-06	2.64e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—EGFR—malignant glioma	4.08e-06	2.64e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—TP53—malignant glioma	4.07e-06	2.64e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—MYC—malignant glioma	4.06e-06	2.63e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	4.05e-06	2.63e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—TP53—malignant glioma	4.04e-06	2.62e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—PIK3CA—malignant glioma	4.03e-06	2.61e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—MYC—malignant glioma	4.03e-06	2.61e-05	CbGpPWpGaD
Loxapine—CHRM5—Signaling Pathways—AKT1—malignant glioma	4.02e-06	2.6e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—MYC—malignant glioma	4.01e-06	2.6e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—STAT3—malignant glioma	4.01e-06	2.6e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—EGFR—malignant glioma	4.01e-06	2.6e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	4.01e-06	2.6e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—EGFR—malignant glioma	4e-06	2.59e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—EGFR—malignant glioma	3.99e-06	2.58e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—EGFR—malignant glioma	3.98e-06	2.58e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—EGFR—malignant glioma	3.94e-06	2.55e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—EGFR—malignant glioma	3.93e-06	2.54e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—PIK3CA—malignant glioma	3.9e-06	2.53e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—TP53—malignant glioma	3.9e-06	2.53e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—TP53—malignant glioma	3.88e-06	2.51e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—KRAS—malignant glioma	3.85e-06	2.49e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—PIK3CA—malignant glioma	3.84e-06	2.49e-05	CbGpPWpGaD
Loxapine—DRD1—Signaling Pathways—AKT1—malignant glioma	3.83e-06	2.48e-05	CbGpPWpGaD
Loxapine—ADRA2C—Metabolism—AKT1—malignant glioma	3.81e-06	2.47e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—KRAS—malignant glioma	3.79e-06	2.45e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—PIK3CA—malignant glioma	3.79e-06	2.45e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—KRAS—malignant glioma	3.78e-06	2.45e-05	CbGpPWpGaD
Loxapine—DRD3—Signaling Pathways—AKT1—malignant glioma	3.78e-06	2.45e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—TP53—malignant glioma	3.77e-06	2.44e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—KRAS—malignant glioma	3.77e-06	2.44e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—KRAS—malignant glioma	3.76e-06	2.43e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—MYC—malignant glioma	3.73e-06	2.42e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—KRAS—malignant glioma	3.72e-06	2.41e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—TP53—malignant glioma	3.71e-06	2.41e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—KRAS—malignant glioma	3.71e-06	2.4e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—EGFR—malignant glioma	3.65e-06	2.36e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—PIK3CA—malignant glioma	3.54e-06	2.29e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	3.48e-06	2.26e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—PIK3CA—malignant glioma	3.47e-06	2.25e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—PIK3CA—malignant glioma	3.46e-06	2.24e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—PIK3CA—malignant glioma	3.45e-06	2.24e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—KRAS—malignant glioma	3.45e-06	2.23e-05	CbGpPWpGaD
Loxapine—ADRB1—Signaling Pathways—AKT1—malignant glioma	3.44e-06	2.23e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—TP53—malignant glioma	3.42e-06	2.22e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—PIK3CA—malignant glioma	3.42e-06	2.21e-05	CbGpPWpGaD
Loxapine—ADRA2B—Signaling Pathways—AKT1—malignant glioma	3.41e-06	2.21e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—PIK3CA—malignant glioma	3.41e-06	2.21e-05	CbGpPWpGaD
Loxapine—CHRM3—Metabolism—AKT1—malignant glioma	3.37e-06	2.18e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—TP53—malignant glioma	3.37e-06	2.18e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—TP53—malignant glioma	3.36e-06	2.18e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—TP53—malignant glioma	3.35e-06	2.17e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—TP53—malignant glioma	3.34e-06	2.16e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—TP53—malignant glioma	3.31e-06	2.14e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—TP53—malignant glioma	3.3e-06	2.14e-05	CbGpPWpGaD
Loxapine—HTR1A—Signaling Pathways—AKT1—malignant glioma	3.29e-06	2.13e-05	CbGpPWpGaD
Loxapine—HTR2C—Signaling Pathways—AKT1—malignant glioma	3.27e-06	2.12e-05	CbGpPWpGaD
Loxapine—ADRA2C—Signaling Pathways—AKT1—malignant glioma	3.18e-06	2.06e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	3.17e-06	2.05e-05	CbGpPWpGaD
Loxapine—ADRA1B—Signaling Pathways—AKT1—malignant glioma	3.13e-06	2.03e-05	CbGpPWpGaD
Loxapine—ADRA2A—Metabolism—AKT1—malignant glioma	3.09e-06	2e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—TP53—malignant glioma	3.06e-06	1.99e-05	CbGpPWpGaD
Loxapine—DRD2—Signaling Pathways—AKT1—malignant glioma	2.89e-06	1.87e-05	CbGpPWpGaD
Loxapine—HTR2A—Signaling Pathways—AKT1—malignant glioma	2.84e-06	1.84e-05	CbGpPWpGaD
Loxapine—HRH1—Signaling Pathways—AKT1—malignant glioma	2.84e-06	1.84e-05	CbGpPWpGaD
Loxapine—CHRM1—Signaling Pathways—AKT1—malignant glioma	2.83e-06	1.83e-05	CbGpPWpGaD
Loxapine—CHRM3—Signaling Pathways—AKT1—malignant glioma	2.82e-06	1.83e-05	CbGpPWpGaD
Loxapine—CHRM2—Signaling Pathways—AKT1—malignant glioma	2.79e-06	1.81e-05	CbGpPWpGaD
Loxapine—ADRA1A—Signaling Pathways—AKT1—malignant glioma	2.78e-06	1.8e-05	CbGpPWpGaD
Loxapine—ADRA2A—Signaling Pathways—AKT1—malignant glioma	2.59e-06	1.68e-05	CbGpPWpGaD
